Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Soochow UniversityActive in the last 2 years

Zhihua Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1660-8534; OpenAlex author ID A5003507789. Sources: OpenAlex.

Their work

Papers
5 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2019: 1 paper · 2020: 3 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 5

  1. Nigericin Suppresses the Wnt/β-catenin Signaling in Pancreatic Cancer Through Targeting Pre-miR-374b-PRKCA/HBP1 Axis. Last author DOI 10.1002/mc.70008↗
  2. MicroRNA-122-5p inhibits cell proliferation, migration and invasion by targeting CCNG1 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12935-020-01185-z↗
  3. Nigericin Suppresses the Wnt/β-catenin Signaling in Pancreatic Cancer through Targeting pre-miR-374b-PRKCA/HBP1 Axis Co-author DOI 10.21203/rs.3.rs-52126/v1↗
  4. Molecular Screening for Nigericin Treatment in Pancreatic Cancer by High-Throughput RNA Sequencing. Co-author DOI 10.3389/fonc.2020.01282↗
  5. High-throughput sequencing of circRNAs reveals novel insights into mechanisms of nigericin in pancreatic cancer. Co-author DOI 10.1186/s12864-019-6032-3↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qiaoming Zhi · 3 shared papers, 2019–2025 · strength 0.50
  2. Fei Liu · 2 shared papers, 2019–2025 · strength 0.39
  3. Chen Dai · 2 shared papers, 2020 · strength 0.27
  4. Mengxian Jin · 1 shared paper, 2020 · strength 0.16
  5. Wei Li · 1 shared paper, 2020 · strength 0.11
  6. Dongming Zhu · 1 shared paper, 2020 · strength 0.11
  7. Ye Xu · 1 shared paper, 2020 · strength 0.11
  8. Min Jiang · 1 shared paper, 2020 · strength 0.11
  9. Ye Xu · 1 shared paper, 2020 · strength 0.11
  10. Zhiyong Du · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.